Oncology's trojan horse: Using Viruses to battle cancer

Consultant Pharmacist

Volumn 31, Issue 12, 2016, Pages 676-684

  Mavani, Heena J ^c   Wick, Jeannette Y ^c   Russell, Stephen ^a   Sharma, Padmanee ^b  

^a MAYO CLINIC CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Cancer; Elderly; Immunotherapy; Lytic; Oncolytic viruses; T Vec; Virotherapy

Indexed keywords

COLONY STIMULATING FACTOR; ONCOLYTIC VIRUS; TALIMOGENE LAHERPAREPVEC; BIOLOGICAL MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER MORTALITY; CANCER RESEARCH; CLINICAL RESEARCH; DNA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MELANOMA; NEWCASTLE DISEASE VIRUS; ONCOLOGY; ONCOLYTIC VIROTHERAPY; PHARMACIST; VIRUS REPLICATION; VIRUS VIRULENCE; AGE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DRUG ADMINISTRATION ROUTE; NEOPLASMS; PROCEDURES;

AGE FACTORS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DRUG ADMINISTRATION ROUTES; HUMANS; MELANOMA; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 85007302477     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2016.676     Document Type: Article

References (24)

1. Mayo Clinic. Harnessing viruses to treat cancer. Mol Med Web. Accessed September 13, 2016.
2. Mendes E. Immunotherapy: disrupting the cancer treatment world. ACS Web. Accessed September 13, 2016.
3. American Cancer Society. Cancer facts and figures 2016. Available at https://www.cancer.gov/about-cancer/understanding/statistics. Accessed October 4, 2016.
4. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007;15:651-9.
5. HBO. VICE: killing cancer. Available at http://killingcancer.vice. com/. Accessed September 30, 2016.
6. Grady D. In Girl's Last Hope, Altered Immune Cells Beat Leukemia. Available at http://www.nytimes.com/2012/12/10/health/a-breakthrough-against-leukemia-using-altered-t-cells.html?-r=1. Accessed September 25, 2016.
7. Grupp SA, Maude SL, Shaw PA et al. Durable remissions in children with relapsed/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood 2015;126:681.
8. Novartis. Novartis highlights new CTL019 phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL. Available at https://www.novartis.com/news/media-releases/novartishighlights-new-ctl019-phase-ii-data-demonstrating-93-completeremission. Accessed October 28, 2016.
9. Printz C. Failure rate: why many cancer drugs don't receive FDA approval, and what can be done about it. Cancer 2015;121:1529-30. doi: 10.1002/cncr.28994.
10. Amiri-Kordestani L, Fojo T. Why do phase III clinical trials in oncology fail so often? JNCI J Natl Cancer Inst 2012 doi: 10.1093/jnci/djs180.
11. Dock G. Rabies virus vaccination in a patient with cervical carcinoma. Am J Med Sci 1904;127:563.
12. Smith R, Huebner RJ, Rowe WP et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9:1211-8.
13. American Journal of Pathology report. Am J Pathol 1964.
14. Martuza RL, Malick A, Markert JM et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252:854-6.
15. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006;98:298-300.
16. Andtbacka R, Kaufman HL, Collichio F et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015;33:2780-8.
17. Schmidt C. Oncolytic virus approved to treat melanoma. J Natl Cancer Inst 2016;108. doi: 10.1093/jnci/djw140.
18. Xi L, Pham TH, Payabyab EC et al. Circulating tumor DNA as an early indicator of response to T-cell transfer immunotherapy in metastatic melanoma. Clin Cancer Res 2016 Aug. 1[E-pub ahead of print].
19. Sirous R, Henegan JC, Zhang X et al. Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies. Abdom Radiol 2016;41:1086-99.
20. National Cancer Institute. Available at https://www.cancer.gov/about-nci/budget. Accessed September 23, 2016.
21. Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci 2016. doi: 10.1111/cas.13027.
22. Wong H, Lemoine NR, Wang Y. Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses 2.1. 2010:78-106.
23. Papaioannou NE, Beniata O V, Vitsos P et al. Harnessing the immune system to improve cancer therapy. Ann Transl Med 2016;4:261. doi:10.21037/atm.2016.04.01.
24. Chernajovsky Y, Layward L, Lemoine N. Fighting cancer with oncolytic viruses. BMJ 2006:170-2.